Infinity Pharmaceuticals Inc (INFI.OQ)
INFI.OQ on NASDAQ Stock Exchange Global Select Market
2.24USD
20 Apr 2018
2.24USD
20 Apr 2018
Change (% chg)
$0.04 (+1.82%)
$0.04 (+1.82%)
Prev Close
$2.20
$2.20
Open
$2.24
$2.24
Day's High
$2.24
$2.24
Day's Low
$2.16
$2.16
Volume
44,376
44,376
Avg. Vol
160,671
160,671
52-wk High
$3.75
$3.75
52-wk Low
$0.93
$0.93
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2017 | Dec '17 | 0.00 | -0.144 |
| Sep '17 | 6.00 | -0.140 | |
| Jun '17 | 0.00 | -0.336 | |
| Mar '17 | 0.00 | -0.208 | |
| FY 2016 | Dec '16 | 0.00 | -0.458 |
| Sep '16 | 0.00 | -0.393 | |
| Jun '16 | 9.47 | 1.072 | |
| Mar '16 | 9.26 | -0.824 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 4 | 7.43 | 29.70 | 0.00 | 39.60 |
| Quarter Ending Sep-18 | 4 | 7.43 | 29.70 | 0.00 | 39.60 |
| Year Ending Dec-18 | 4 | 0.50 | 2.00 | 0.00 | 39.58 |
| Year Ending Dec-19 | 4 | 11.00 | 22.00 | 0.00 | 0.00 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 4 | -0.19 | -0.19 | -0.20 | -0.68 |
| Quarter Ending Sep-18 | 4 | -0.19 | -0.17 | -0.20 | -0.68 |
| Year Ending Dec-18 | 4 | -0.73 | -0.70 | -0.77 | -1.44 |
| Year Ending Dec-19 | 4 | -0.59 | -0.38 | -0.90 | -0.93 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 84.02 | 32.74 | |
| P/E High - Last 5 Yrs. | -- | 293.18 | 45.72 | |
| P/E Low - Last 5 Yrs. | -- | 91.59 | 24.22 | |
| Beta | 2.69 | 0.90 | 0.88 | |
| Price to Sales (TTM) | -- | 110.89 | 5.71 | |
| Price to Book (MRQ) | 1.36 | 13.58 | 5.37 | |
| Price to Tangible Book (MRQ) | 1.37 | 14.04 | 6.95 | |
| Price to Cash Flow (TTM) | -- | 71.40 | 23.32 | |
| % Owned Institutions | 71.60 | 12.75 | 2.17 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.31 | 1.50 | |
| Dividend Yield - 5 Year Avg | -- | 0.26 | 1.51 | |
| Dividend 5 Year Growth Rate | -- | 1.66 | 5.32 | |
| Payout Ratio(TTM) | -- | 15.72 | 43.29 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -100.00 | 399.08 | 9.21 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -100.00 | 78.82 | 5.69 | |
| Sales - 5 Yr. Growth Rate | -27.39 | 32.16 | 10.32 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -131.35 | 25.00 | 19.36 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -581.56 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 38.99 | 10.76 | |
| Capital Spending - 5 Yr. Growth Rate | -15.59 | 40.29 | 15.47 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.80 | 2.19 |
| Current Ratio (MRQ) | 6.29 | 5.30 | 2.98 |
| LT Debt to Equity (MRQ) | 35.31 | 22.96 | 12.18 |
| Total Debt to Equity (MRQ) | 36.09 | 24.62 | 16.45 |
| Interest Coverage (TTM) | -- | -99.35 | 32.81 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 40.02 | 54.44 | |
| Gross Margin - 5 Yr. Avg. | -- | 51.13 | 52.20 | |
| EBITD Margin (TTM) | -- | -- | -- | |
| EBITD - 5 Yr. Avg | -146.16 | -574.75 | 10.96 | |
| Operating Margin (TTM) | -- | -718.53 | 4.73 | |
| Operating Margin - 5 Yr. Avg. | -101.91 | -596.06 | 6.40 | |
| Pre-Tax Margin (TTM) | -- | -693.00 | 5.57 | |
| Pre-Tax Margin - 5 Yr. Avg. | -104.77 | -599.42 | 6.81 | |
| Net Profit Margin (TTM) | -- | -694.22 | 1.87 | |
| Net Profit Margin - 5 Yr. Avg. | -104.92 | -602.27 | 3.09 | |
| Effective Tax Rate (TTM) | -- | 22.62 | 23.04 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 18.21 | 23.96 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 0 | 22,626,821 | 846,830,978 | |
| Net Income/Employee (TTM) | -3,037,261 | 2,971,371 | 99,616,195 | |
| Receivable Turnover (TTM) | -- | 20.16 | 5.78 | |
| Inventory Turnover (TTM) | -- | 2.37 | 3.35 | |
| Asset Turnover (TTM) | 0.00 | 0.39 | 0.92 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -50.23 | -1.11 | 10.95 | |
| Return on Assets - 5 Yr. Avg. | -26.43 | -0.57 | 12.31 | |
| Return on Investment (TTM) | -62.67 | 1.58 | 14.38 | |
| Return on Investment - 5 Yr. Avg. | -30.82 | 2.21 | 16.10 | |
| Return on Equity (TTM) | -78.61 | 2.41 | 16.07 | |
| Return on Equity - 5 Yr. Avg. | -41.07 | 3.09 | 17.39 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -82.83 | -- | -27.39 |
| EPS (TTM) % | 76.80 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Infinity Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 31.40 | 26.87 | 90 | 53 |
| 13 Week | 5.30 | 0.17 | 61 | 65 |
| 26 Week | -34.30 | -39.29 | 18 | 77 |
| 52 Week | 3.25 | -12.49 | 52 | 50 |
| YTD | 17.78 | 3.43 | 57 | 58 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-BVF Partners Reports 21.7 Pct Stake In Infinity Pharmaceuticals As Of April 10
- BRIEF-Infinity Pharma Qtrly Diluted Loss Per Common Share $0.14
- BRIEF-Infinity Expects Net Loss For 2018 To Range From $40 Mln To $50 Mln
- BRIEF-Infinity Pharmaceuticals reports phase 1 clinical and translational data for IPI-549
- BRIEF-Infinity Q3 loss per share $0.14
Institutional Holders
| % Shares Owned: | 55.72% |
| # of Holders: | 84 |
| Total Shares Held: | 28,953,367 |
| 3 Mo. Net Change: | 1,682,907 |
| # New Positions: | 0 |
| # Closed Positions: | 1 |
| # Increased Positions: | 3 |
| # Reduced Positions: | 1 |
| # Net Buyers: | 2 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.